FDA proposes permanently barring semaglutide from 503B bulk compounding

The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from the list of bulk drug substances that 503B outsourcing facilities are allowed to compound ^[1]. In late June the agency extended the public comment deadline on the proposal from June 30 to July 30, 2026, after industry groups said the original window was too short; they requested 60 extra days and received 30 ^[1].

The sources differ on the timing and scope of the proposal itself. One account places the proposal in May 2026 and says it covers semaglutide, tirzepatide and liraglutide ^[1]. Another says the FDA formally proposed removing semaglutide and tirzepatide from the 503B Bulk Drug Substances List on April 30, 2026, with a comment period running through June 29, 2026 ^[2]. Both agree the direction is the same: a near-total end to large-scale 503B compounding of these drugs ^[1][2].

What a 503B facility is

Federal law splits compounding into two tracks. A 503A pharmacy is state-licensed and compounds for one specific patient with a specific prescription ^[1][2]. A 503B outsourcing facility registers with the FDA, follows current Good Manufacturing Practice standards, and makes large batches without patient-specific prescriptions ^[1][2]. That batch model is what allowed high-volume telehealth semaglutide programs to supply tens of thousands of people at once ^[1]. The proposed exclusion would close that pipeline, but it would not eliminate the narrower 503A pathway, which still allows compounding for a documented patient-specific clinical need such as an excipient allergy or a dose not commercially available ^[2]. Cost alone is not a recognized basis for 503A compounding ^[2].

The enforcement build-up

The proposal follows more than a year of pressure. The FDA declared the semaglutide shortage resolved in February 2025 and set cutoffs of April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities to stop making products that were "essentially a copy" of the approved drug ^[2]. Court injunctions in mid-2025 temporarily shielded some 503B operators ^[2].

Warning letters followed in waves: roughly 80 to telehealth companies in September 2025 ^[1], and a large coordinated wave in March 2026. Here the sources disagree on size — one says about 30 letters ^[1], the other says more than 50, describing it as the largest action against GLP-1 compounders in U.S. history ^[2]. A third wave of 25 letters went out during the week of June 15, 2026, again citing claims that a compounded product is the "same" as the approved drug and marketing that never names the compounding pharmacy ^[1]. In April 2026 the FDA clarified that compounders cannot sell what amounts to a copy of a commercially available drug at the same or similar strength; legal analysts note the clarification does not carry the force of law but signals enforcement intent ^[1][2].

Why it matters for patients

Nothing changes on July 31. The comment deadline is not a shutdown date, and compounded semaglutide remains legal to buy while the rule is only a proposal ^[1]. If the exclusion is finalized, 503B facilities would have to stop bulk production of these drugs, and supply feeding most large compounded GLP-1 programs would shrink from the top ^[1].

The price gap that drove the compounded market has narrowed. Compounded semaglutide has typically cost $150 to $400 a month, versus $935 to $1,349 for brand-name Ozempic or Wegovy without insurance ^[2]. An oral form of Wegovy approved December 22, 2025 is listed at $149 a month without insurance; in trials, participants lost about 17% of body weight versus 2.7% on placebo ^[1].

Safety data is part of the FDA's rationale. As of April 30, 2025, the agency had received 520 adverse event reports tied to compounded semaglutide ^[2]; another tally cites more than 455 for semaglutide and more than 320 for tirzepatide as of early 2025 ^[1]. Many involve dosing errors, including patients taking 5 to 20 times the intended dose because of confusion between units and mg/mL in multi-dose vials ^[2].

What happens next

Comments close July 30, 2026 ^[1]. The FDA then reviews them and decides when to finalize. No decision date has been published ^[1], though some industry analysts expect finalization in the third quarter of 2026 ^[2]. Whether the comments change the outcome is not yet known.